Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Teclegiorgis Gebremariam; Sondus Alkhazraji; Lin Lin; Nathan P. Wiederhold; Edward P. Garvey; William J. Hoekstra; Robert J. Schotzinger; Thomas F. Patterson; Scott G. Filler; Ashraf S. Ibrahim

doi:10.1128/AAC.00390-17

Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Teclegiorgis Gebremariam, Sondus Alkhazraji, Lin Lin, Nathan P. Wiederhold, Edward P. Garvey, William J. Hoekstra, Robert J. Schotzinger, Thomas F. Patterson, Scott G. Filler, Ashraf S. Ibrahim

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

Original language	English (US)
Article number	e00390-17
Journal	Antimicrobial agents and chemotherapy
Volume	61
Issue number	9
DOIs	https://doi.org/10.1128/AAC.00390-17
State	Published - Sep 2017

Keywords

Mucormycosis
Murine
Prophylaxis
Rhizopus arrhizus
VT-1161

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Access to Document

10.1128/AAC.00390-17

Cite this

Gebremariam, T., Alkhazraji, S., Lin, L., Wiederhold, N. P., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2017). Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection. Antimicrobial agents and chemotherapy, 61(9), Article e00390-17. https://doi.org/10.1128/AAC.00390-17

@article{4ed17ce7f63f46108abba6b76c35ca8c,

title = "Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection",

abstract = "We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.",

keywords = "Mucormycosis, Murine, Prophylaxis, Rhizopus arrhizus, VT-1161",

author = "Teclegiorgis Gebremariam and Sondus Alkhazraji and Lin Lin and Wiederhold, \{Nathan P.\} and Garvey, \{Edward P.\} and Hoekstra, \{William J.\} and Schotzinger, \{Robert J.\} and Patterson, \{Thomas F.\} and Filler, \{Scott G.\} and Ibrahim, \{Ashraf S.\}",

year = "2017",

month = sep,

doi = "10.1128/AAC.00390-17",

language = "English (US)",

volume = "61",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "9",

}

TY - JOUR

T1 - Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

AU - Gebremariam, Teclegiorgis

AU - Alkhazraji, Sondus

AU - Lin, Lin

AU - Wiederhold, Nathan P.

AU - Garvey, Edward P.

AU - Hoekstra, William J.

AU - Schotzinger, Robert J.

AU - Patterson, Thomas F.

AU - Filler, Scott G.

AU - Ibrahim, Ashraf S.

PY - 2017/9

Y1 - 2017/9

N2 - We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

AB - We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

KW - Mucormycosis

KW - Murine

KW - Prophylaxis

KW - Rhizopus arrhizus

KW - VT-1161

UR - https://www.scopus.com/pages/publications/85028326528

UR - https://www.scopus.com/inward/citedby.url?scp=85028326528&partnerID=8YFLogxK

U2 - 10.1128/AAC.00390-17

DO - 10.1128/AAC.00390-17

M3 - Article

C2 - 28652241

AN - SCOPUS:85028326528

SN - 0066-4804

VL - 61

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 9

M1 - e00390-17

ER -

Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this